The occurrence of mutant KRAS clones in the blood of RAS wild type colorectal cancer patients - impact of response or failure under anti-EGFR therapy

被引：0
|
作者：
Berger, A. W. [1 ]
Schwerdel, D. [1 ]
Welz, H. [1 ]
Moeller, P. [2 ]
Ettrich, T. J. [1 ]
Seufferlein, T. [1 ]
机构：
[1] Univ Ulm Klinikum, Klin Innere Med 1, Ulm, Germany
[2] Univ Ulm Klinikum, Inst Pathol, Ulm, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0514
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [31] Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
    Tougeron, D.
    Lecomte, T.
    Pages, J. C.
    Villalva, C.
    Collin, C.
    Ferru, A.
    Tourani, J. M.
    Silvain, C.
    Levillain, P.
    Karayan-Tapon, L.
    ANNALS OF ONCOLOGY, 2013, 24 (05) : 1267 - 1273
  • [32] Plasma RAS mutations for the selection and monitoring of colorectal cancer patients treated with anti-EGFR therapy
    Vidal, Joana
    Dalmases, Alba
    Vela, Maria Carmen
    Muset, Maria Merce
    Piquer, Gabriel
    Visa, Laura
    Correa, Roser
    Martinez, Gemma
    Sikri, Vishal
    Tusquets, Ignacio
    Albanell, Joan
    Jones, Frederick S.
    Bellosillo, Beatriz
    Montagut, Clara
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] HSA-MIR31-3P EXPRESSION AS A PREDICTOR OF ANTI-EGFR RESPONSE IN WILD-TYPE KRAS PATIENTS WITH METASTATIC COLORECTAL CANCER
    Laurent-Puig, P.
    Manceau, G.
    Bachet, J.
    Chibaudel, B.
    Liebaert, F.
    Bouche, O.
    Penault-Llorca, F.
    Diebold, M. D.
    Andre, T.
    Imbeaud, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 180 - 180
  • [34] Impact of optimal morphologic response on survival in patients with KRAS wild-type unresectable colorectal liver metastases receiving an anti-EGFR or anti-VEGF agent
    Masuishi, T.
    Taniguchi, H.
    Narita, Y.
    Komori, A.
    Nomura, M.
    Kadowaki, S.
    Andoh, M.
    Ura, T.
    Eto, T.
    Muro, K.
    ANNALS OF ONCOLOGY, 2015, 26
  • [35] From KRAS mutations to RAS mutations: Towards a better definition of response to anti-EGFR antibodies in metastatic colorectal cancer
    Lievre, A.
    ONCOLOGIE, 2014, 16 (2-3) : 120 - 128
  • [36] Treatment of extended RAS/ BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations
    Voutsadakis, Ioannis A.
    PHARMACOGENOMICS, 2025,
  • [37] Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
    Wang, Chongkai
    Sandhu, Jaideep
    Fakih, Marwan
    ONCOLOGIST, 2022, 27 (02): : 104 - 109
  • [38] Multi-omics signature for identification of RAS wild-type colorectal cancer liver metastases sensitive to anti-EGFR therapy
    Liu, Y.
    Zhou, S.
    Chen, Y.
    Xiao, X.
    Wang, L.
    Yu, R.
    Chang, W.
    Xu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1535 - S1535
  • [39] MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF
    Mosakhani, Neda
    Lahti, Leo
    Borze, Ioana
    Karjalainen-Lindsberg, Marja-Liisa
    Sundstrom, Jari
    Ristamaki, Raija
    Osterlund, Pia
    Knuutila, Sakari
    Sarhadi, Virinder Kaur
    CANCER GENETICS, 2012, 205 (11) : 545 - 551
  • [40] The secondary mutation of KRAS and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer
    Xia, X.
    Du, W.
    Zhu, Y.
    Bai, Y.
    Liu, M.
    CLINICAL & EXPERIMENTAL METASTASIS, 2017, 34 (3-4) : 218 - 218
12345